|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023474,
umls-concept:C0030705,
umls-concept:C0035696,
umls-concept:C0036667,
umls-concept:C0205360,
umls-concept:C0243161,
umls-concept:C0312418,
umls-concept:C0332232,
umls-concept:C0332293,
umls-concept:C0439234,
umls-concept:C0441889,
umls-concept:C0549178,
umls-concept:C0935989,
umls-concept:C1522326,
umls-concept:C1977882,
umls-concept:C2825407
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
In the first years of imatinib treatment, BCR-ABL remained detectable in all but a small minority of patients with chronic myeloid leukemia. We determined whether BCR-ABL continues to decline with longer imatinib exposure and the incidence and consequence of undetectable BCR-ABL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7080-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18056186-Antineoplastic Agents,
pubmed-meshheading:18056186-Clinical Trials as Topic,
pubmed-meshheading:18056186-Fusion Proteins, bcr-abl,
pubmed-meshheading:18056186-Humans,
pubmed-meshheading:18056186-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:18056186-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:18056186-Mutation,
pubmed-meshheading:18056186-Piperazines,
pubmed-meshheading:18056186-Polymerase Chain Reaction,
pubmed-meshheading:18056186-Pyrimidines,
pubmed-meshheading:18056186-RNA, Messenger,
pubmed-meshheading:18056186-Remission Induction,
pubmed-meshheading:18056186-Sensitivity and Specificity
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
|
|
pubmed:affiliation |
Institute of Medical and Veterinary Science, Adelaide, Australia. susan.branford@imvs.sa.gov.au
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
